Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 21Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Follicular 9Leukemia, Myeloid, Acute 9Hodgkin Disease 7Lymphoma, Mantle-Cell 6Lymphoma, Large B-Cell, Diffuse 6Leukemia 6Myelodysplastic Syndromes 5Multiple Myeloma 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Hematologic Neoplasms 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Burkitt Lymphoma 4Stomach Neoplasms 3Recurrence 3Lymphoma, Large-Cell, Immunoblastic 3Colorectal Neoplasms 3Waldenstrom Macroglobulinemia 2Neoplasms 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myelomonocytic, Juvenile 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1

Interventions

pembrolizumab 2fludarabine 1epacadostat 1atezolizumab 1aldesleukin 1Nivolumab 1Interleukin-2 1Cyclophosphamide 1Carboxylesterase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite Instability × Interleukin-2 × Lymphoid × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡